Earliest Stage Treatment of Aktinic Keratosis With Imiquimod 3.75% Cream

Phase 4

Completed

• Conditions: Actinic Keratoses
• Interventions: Drug: Imiquimod 3.75% Cream

• Registration Number: NCT04842422
• Lead Sponsor: Medical University of Graz

Brief Summary

Earliest Stage Treatment of Actinic Keratosis with Imiquimod 3.75% Cream:

The study is to demonstrate that Aktinic Keratosis are present before they are clinically visible, i.e. in a subclinical stage. Since on the basis of the research situation, also subclinical AK can proliferate into the dermis, it is possible that with the application of Imiquimod on chronically light-exposed skin, undetected squamous cell carcinoma can be recognized and treated at the same time.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2021-04-08
• Study First Submitted QC: 2021-04-08
• Study First Posted: 2021-04-13
• Study Start: 2021-04-16
• Primary Completion: 2021-08-23
• Study Completion: 2021-08-23
• Status Verified: 2022-01
• Last Update Submitted: 2022-01-10
• Last Update Posted: 2022-01-11

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Female
• Target Recruitment: 48

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Earliest Stage Treatment of Aktinic Keratosis	Imiquimod 3.75% Cream	-

Primary Outcome Measures

Name	Time	Method
immunomodulatory-induced inflammatory reaction	two weeks	Percentage of subjects in whom an immunomodulatory-induced inflammatory reaction occurs on chronically light-exposed uv-damaged facial skin after two weeks.

Trial Locations

Locations (1)

Universitätsklinik für Dermatologie und Venerologie; 🇦🇹 Graz, Austria